Pregled bibliografske jedinice broj: 1106550
A rare case of hypocalcemia induced by nilotinib
A rare case of hypocalcemia induced by nilotinib // Endocrine oncology and metabolism, 3 (2017), 1; 32-35 doi:10.21040/eom/2017.3.1.5 (domaća recenzija, članak, znanstveni)
CROSBI ID: 1106550 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
A rare case of hypocalcemia induced by nilotinib
Autori
Petrić, Marija ; Miljak, Antonija ; Miličević, Tanja ; Radman, Maja
Izvornik
Endocrine oncology and metabolism (1849-8922) 3
(2017), 1;
32-35
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Chronic myelogenous leukemia ; Tyrosine kinase inhibitors ; Nilotinib ; Side effects ; Hypocalcemia ; QT interval
Sažetak
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by increased proliferation of predominantly myeloid cells in the bone marrow and their accumulation in the peripheral blood. Nowadays, drugs known as tyrosine kinase inhibitors (TKIs) are the standard treatment for CML. Since TKIs specifically target BCR-ABL, the activated tyrosine kinase fusion protein, they are expected to cause less hematological and nonhematological side effects than medications used before. We report a case of a 61-year-old patient treated with the second-generation TKI, nilotinib, that presented with very common side effects (skin rash, myalgia, and paresthesia), and also with rare, but severe hypocalcemia and potentially dangerous and fatal QTc elongation.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
